Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening.

Puligedda RD, Sharma R, Al-Saleem FH, Kouiavskaia D, Velu AB, Kattala CD, Prendergast GC, Lynch DR, Chumakov K, Dessain SK.

MAbs. 2019 Apr;11(3):546-558. doi: 10.1080/19420862.2019.1574520. Epub 2019 Feb 22.

2.

Sabin Strain Inactivated Polio Vaccine for the Polio Endgame.

Modlin J, Chumakov K.

J Infect Dis. 2019 Feb 21. pii: jiz077. doi: 10.1093/infdis/jiz077. [Epub ahead of print] No abstract available.

PMID:
30788498
3.

Possible long-term sequelae in hand, foot, and mouth disease caused by Coxsackievirus A6.

Broccolo F, Drago F, Ciccarese G, Genoni A, Porro A, Parodi A, Chumakov K, Toniolo A.

J Am Acad Dermatol. 2019 Mar;80(3):804-806. doi: 10.1016/j.jaad.2018.08.034. Epub 2019 Jan 17. No abstract available.

PMID:
30661911
4.

Severe atypical hand-foot-and-mouth disease in adults due to coxsackievirus A6: Clinical presentation and phylogenesis of CV-A6 strains.

Broccolo F, Drago F, Ciccarese G, Genoni A, Puggioni A, Rosa GM, Parodi A, Manukyan H, Laassri M, Chumakov K, Toniolo A.

J Clin Virol. 2019 Jan;110:1-6. doi: 10.1016/j.jcv.2018.11.003. Epub 2018 Nov 17.

PMID:
30472520
5.

Detection of bovine viral diarrhoea virus nucleic acid, but not infectious virus, in bovine serum used for human vaccine manufacture.

Laassri M, Mee ET, Connaughton SM, Manukyan H, Gruber M, Rodriguez-Hernandez C, Minor PD, Schepelmann S, Chumakov K, Wood DJ.

Biologicals. 2018 Sep;55:63-70. doi: 10.1016/j.biologicals.2018.06.002. Epub 2018 Jun 23.

PMID:
29941334
6.

Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.

Viktorova EG, Khattar SK, Kouiavskaia D, Laassri M, Zagorodnyaya T, Dragunsky E, Samal S, Chumakov K, Belov GA.

J Virol. 2018 Aug 16;92(17). pii: e00976-18. doi: 10.1128/JVI.00976-18. Print 2018 Sep 1.

7.

Quantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimens.

Manukyan H, Zagorodnyaya T, Ruttimann R, Manor Y, Bandyopadhyay A, Shulman L, Chumakov K, Laassri M.

J Virol Methods. 2018 Sep;259:74-80. doi: 10.1016/j.jviromet.2018.06.009. Epub 2018 Jun 18.

8.

Evolution of echovirus 11 in a chronically infected immunodeficient patient.

Laassri M, Zagorodnyaya T, Hassin-Baer S, Handsher R, Sofer D, Weil M, Karagiannis K, Simonyan V, Chumakov K, Shulman L.

PLoS Pathog. 2018 Mar 19;14(3):e1006943. doi: 10.1371/journal.ppat.1006943. eCollection 2018 Mar.

9.

Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures.

White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE Jr, Maes EF, Oberste MS, Snider CJ, Anand A, Chen D.

Biologicals. 2018 May;53:30-38. doi: 10.1016/j.biologicals.2018.03.002. Epub 2018 Mar 14.

10.

Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications.

Korotkova E, Laassri M, Zagorodnyaya T, Petrovskaya S, Rodionova E, Cherkasova E, Gmyl A, Ivanova OE, Eremeeva TP, Lipskaya GY, Agol VI, Chumakov K.

Viruses. 2017 Nov 22;9(11). pii: E353. doi: 10.3390/v9110353.

11.

Separation and assembly of deep sequencing data into discrete sub-population genomes.

Karagiannis K, Simonyan V, Chumakov K, Mazumder R.

Nucleic Acids Res. 2017 Nov 2;45(19):10989-11003. doi: 10.1093/nar/gkx755.

12.

Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach.

Genoni A, Canducci F, Rossi A, Broccolo F, Chumakov K, Bono G, Salerno-Uriarte J, Salvatoni A, Pugliese A, Toniolo A.

Sci Rep. 2017 Jul 10;7(1):5013. doi: 10.1038/s41598-017-04993-y.

13.

Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis.

Shen L, Chen CY, Huang D, Wang R, Zhang M, Qian L, Zhu Y, Zhang AZ, Yang E, Qaqish A, Chumakov K, Kouiavskaia D, Vignuzzi M, Nathanson N, Macadam AJ, Andino R, Kew O, Xu J, Chen ZW.

J Virol. 2017 Jun 26;91(14). pii: e02310-16. doi: 10.1128/JVI.02310-16. Print 2017 Jul 15.

14.

Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.

Puligedda RD, Kouiavskaia D, Al-Saleem FH, Kattala CD, Nabi U, Yaqoob H, Bhagavathula VS, Sharma R, Chumakov K, Dessain SK.

Vaccine. 2017 Oct 4;35(41):5455-5462. doi: 10.1016/j.vaccine.2017.03.038. Epub 2017 Mar 24.

PMID:
28343771
15.

HIVE-heptagon: A sensible variant-calling algorithm with post-alignment quality controls.

Simonyan V, Chumakov K, Donaldson E, Karagiannis K, Lam PV, Dingerdissen H, Voskanian A.

Genomics. 2017 Jul;109(3-4):131-140. doi: 10.1016/j.ygeno.2017.01.002. Epub 2017 Feb 8.

16.

A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development.

Tsetsarkin KA, Kenney H, Chen R, Liu G, Manukyan H, Whitehead SS, Laassri M, Chumakov K, Pletnev AG.

MBio. 2016 Aug 23;7(4). pii: e01114-16. doi: 10.1128/mBio.01114-16.

17.

Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes.

Chan HT, Xiao Y, Weldon WC, Oberste SM, Chumakov K, Daniell H.

Plant Biotechnol J. 2016 Nov;14(11):2190-2200. doi: 10.1111/pbi.12575. Epub 2016 Jun 1.

18.

Environmental surveillance of viruses by tangential flow filtration and metagenomic reconstruction.

Furtak V, Roivainen M, Mirochnichenko O, Zagorodnyaya T, Laassri M, Zaidi SZ, Rehman L, Alam MM, Chizhikov V, Chumakov K.

Euro Surveill. 2016 Apr 14;21(15). doi: 10.2807/1560-7917.ES.2016.21.15.30193. Erratum in: Euro Surveill. 2016 May 12;21(19):. Zaidic, Sohail Z [corrected to Zaidi, Sohail Z].

19.

High-performance integrated virtual environment (HIVE): a robust infrastructure for next-generation sequence data analysis.

Simonyan V, Chumakov K, Dingerdissen H, Faison W, Goldweber S, Golikov A, Gulzar N, Karagiannis K, Vinh Nguyen Lam P, Maudru T, Muravitskaja O, Osipova E, Pan Y, Pschenichnov A, Rostovtsev A, Santana-Quintero L, Smith K, Thompson EE, Tkachenko V, Torcivia-Rodriguez J, Voskanian A, Wan Q, Wang J, Wu TJ, Wilson C, Mazumder R.

Database (Oxford). 2016 Mar 17;2016. pii: baw022. doi: 10.1093/database/baw022. Print 2016.

20.

Methods to Monitor Molecular Consistency of Oral Polio Vaccine.

Chumakov KM.

Methods Mol Biol. 2016;1387:263-77. doi: 10.1007/978-1-4939-3292-4_14.

PMID:
26983740
21.

Fluorescence Adherence Inhibition Assay: A Novel Functional Assessment of Blocking Virus Attachment by Vaccine-Induced Antibodies.

Asati A, Kachurina O, Karol A, Dhir V, Nguyen M, Parkhill R, Kouiavskaia D, Chumakov K, Warren W, Kachurin A.

PLoS One. 2016 Feb 10;11(2):e0144261. doi: 10.1371/journal.pone.0144261. eCollection 2016.

22.

Eradicating polio: A balancing act.

Agol V, Cello J, Chumakov K, Ehrenfeld E, Wimmer E.

Science. 2016 Jan 22;351(6271):348. doi: 10.1126/science.351.6271.348-b. No abstract available.

PMID:
26798005
23.

Deep Sequencing for Evaluation of Genetic Stability of Influenza A/California/07/2009 (H1N1) Vaccine Viruses.

Laassri M, Zagorodnyaya T, Plant EP, Petrovskaya S, Bidzhieva B, Ye Z, Simonyan V, Chumakov K.

PLoS One. 2015 Sep 25;10(9):e0138650. doi: 10.1371/journal.pone.0138650. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0142248. Majid, Laassri [corrected to Laassri, Majid].

24.

A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Kouiavskaia D, Chen Z, Dragunsky E, Mirochnitchenko O, Purcell R, Chumakov K.

J Clin Virol. 2015 Apr;65:32-7. doi: 10.1016/j.jcv.2015.01.023. Epub 2015 Feb 3.

25.

Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.

Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y.

J Infect Dis. 2015 Jun 15;211(12):1969-76. doi: 10.1093/infdis/jiu841. Epub 2015 Jan 7.

26.

Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

Kouiavskaia D, Mirochnitchenko O, Dragunsky E, Kochba E, Levin Y, Troy S, Chumakov K.

J Infect Dis. 2015 May 1;211(9):1447-50. doi: 10.1093/infdis/jiu624. Epub 2014 Nov 12.

27.

MicroRNAs as potential biomarkers for VERO cell tumorigenicity.

Teferedegne B, Macauley J, Foseh G, Dragunsky E, Chumakov K, Murata H, Peden K, Lewis AM Jr.

Vaccine. 2014 Aug 20;32(37):4799-805. doi: 10.1016/j.vaccine.2014.05.065. Epub 2014 Jul 10.

28.

New small-molecule inhibitors effectively blocking picornavirus replication.

Ford Siltz LA, Viktorova EG, Zhang B, Kouiavskaia D, Dragunsky E, Chumakov K, Isaacs L, Belov GA.

J Virol. 2014 Oct;88(19):11091-107. doi: 10.1128/JVI.01877-14. Epub 2014 Jul 9.

29.

Whole genome single-nucleotide variation profile-based phylogenetic tree building methods for analysis of viral, bacterial and human genomes.

Faison WJ, Rostovtsev A, Castro-Nallar E, Crandall KA, Chumakov K, Simonyan V, Mazumder R.

Genomics. 2014 Jul;104(1):1-7. doi: 10.1016/j.ygeno.2014.06.001. Epub 2014 Jun 12.

30.

Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.

Puligedda RD, Kouiavskaia D, Adekar SP, Sharma R, Devi Kattala C, Rezapkin G, Bidzhieva B, Dessain SK, Chumakov K.

Antiviral Res. 2014 Aug;108:36-43. doi: 10.1016/j.antiviral.2014.05.005. Epub 2014 May 10.

PMID:
24824031
31.

Allele-specific PCR for quantitative analysis of mutants in live viral vaccines.

Bidzhieva B, Laassri M, Chumakov K.

J Virol Methods. 2014 Jun;201:86-92. doi: 10.1016/j.jviromet.2014.02.012. Epub 2014 Mar 7.

32.

Deep sequencing approach for genetic stability evaluation of influenza A viruses.

Bidzhieva B, Zagorodnyaya T, Karagiannis K, Simonyan V, Laassri M, Chumakov K.

J Virol Methods. 2014 Apr;199:68-75. doi: 10.1016/j.jviromet.2013.12.018. Epub 2014 Jan 7.

PMID:
24406624
33.

Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.

Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, Makiya M, Agulto L, Purcell RH, Chumakov K.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20242-7. doi: 10.1073/pnas.1320041110. Epub 2013 Nov 25.

34.

Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants.

Troy SB, Musingwini G, Halpern MS, Huang C, Stranix-Chibanda L, Kouiavskaia D, Shetty AK, Chumakov K, Nathoo K, Maldonado YA.

J Infect Dis. 2013 Aug 15;208(4):672-8. doi: 10.1093/infdis/jit208. Epub 2013 May 9.

35.

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28. Review.

PMID:
23550968
36.

Quantitative one-step RT-PCR assay for rapid and sensitive identification and titration of polioviruses in clinical specimens.

Laassri M, Dipiazza A, Bidzhieva B, Zagorodnyaya T, Chumakov K.

J Virol Methods. 2013 Apr;189(1):7-14. doi: 10.1016/j.jviromet.2012.12.015. Epub 2013 Jan 7.

PMID:
23305817
37.

Expert review on poliovirus immunity and transmission.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Review.

PMID:
22804479
38.

Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children.

Gnanashanmugam D, Troy SB, Musingwini G, Huang C, Halpern MS, Stranix-Chibanda L, Shetty AK, Kouiavskaia D, Nathoo K, Chumakov K, Maldonado YA.

Pediatr Infect Dis J. 2012 Feb;31(2):176-80. doi: 10.1097/INF.0b013e31823faa5f.

PMID:
22146742
39.

Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM.

Antivir Ther. 2011;16(7):999-1004. doi: 10.3851/IMP1838.

PMID:
22024515
40.

WHO Working Group discussion on revision of the WHO recommendations for the production and control of poliomyelitis vaccines (oral): TRS Nos. 904 and 910. Report of Meeting held on 20-22 July 2010, Geneva, Switzerland.

Martin J, Milne C, Minor P, Chumakov K, Baca-Estrada M, Caruana JF, Zhou T; WHO Working Group.

Vaccine. 2011 Sep 2;29(38):6432-6. doi: 10.1016/j.vaccine.2011.06.079. Epub 2011 Jul 3.

PMID:
21729731
41.

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice.

Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, Chumakov KM.

Clin Vaccine Immunol. 2011 Aug;18(8):1387-90. doi: 10.1128/CVI.05147-11. Epub 2011 Jun 29.

42.

Universal oligonucleotide microarray for sub-typing of Influenza A virus.

Ryabinin VA, Kostina EV, Maksakova GA, Neverov AA, Chumakov KM, Sinyakov AN.

PLoS One. 2011 Apr 29;6(4):e17529. doi: 10.1371/journal.pone.0017529.

43.

MAPREC assay for quantitation of mutants in a recombinant flavivirus vaccine strain using near-infrared fluorescent dyes.

Bidzhieva B, Laassri M, Chumakov K.

J Virol Methods. 2011 Jul;175(1):14-9. doi: 10.1016/j.jviromet.2011.04.008. Epub 2011 Apr 14.

PMID:
21514323
44.

Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus.

Laassri M, Bidzhieva B, Speicher J, Pletnev AG, Chumakov K.

J Med Virol. 2011 May;83(5):910-20. doi: 10.1002/jmv.22033. Epub 2011 Feb 25.

45.

Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R.

J Virol. 2011 May;85(9):4354-62. doi: 10.1128/JVI.02553-10. Epub 2011 Feb 23.

46.

Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.

Neverov A, Chumakov K.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20063-8. doi: 10.1073/pnas.1012537107. Epub 2010 Nov 1.

47.

Repertoire of antibodies against type 1 poliovirus in human sera.

Rezapkin G, Neverov A, Cherkasova E, Vidor E, Sarafanov A, Kouiavskaia D, Dragunsky E, Chumakov K.

J Virol Methods. 2010 Nov;169(2):322-31. doi: 10.1016/j.jviromet.2010.07.037. Epub 2010 Aug 4.

PMID:
20691212
48.

Preterm infants' T cell responses to inactivated poliovirus vaccine.

Klein NP, Gans HA, Sung P, Yasukawa LL, Johnson J, Sarafanov A, Chumakov K, Hansen J, Black S, Dekker CL.

J Infect Dis. 2010 Jan 15;201(2):214-22. doi: 10.1086/649590.

PMID:
20017631
49.

Future of polio vaccines.

Ehrenfeld E, Modlin J, Chumakov K.

Expert Rev Vaccines. 2009 Jul;8(7):899-905. doi: 10.1586/erv.09.49. Review.

50.

New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Chumakov K, Ehrenfeld E.

Clin Infect Dis. 2008 Dec 15;47(12):1587-92. doi: 10.1086/593310. Review.

Supplemental Content

Loading ...
Support Center